Here, Mesothelin is a promising potential target antigen for CAR therapies, as it is highly expressed on a multitude of different cancers, including the majority of cervical cancers, but absent in most healthy adult tissues, with limited expression reported in mesothelial linings of the peritoneum, pleura, and pericardium (6, 7). This evidence concerns the gene MSLN and cervical cancer.